Asthma under control
We recommend
Atectura® and Enerzair®: new fixed dual and triple combination in the treatment of bronchial asthma
In mid-2020, the European Commission approved two new fixed combinations of drugs by Novartis for patients with uncontrolled asthma – the dual combination Atectura® (LABA+ICS) and the triple combination Enerzair® (LABA+LAMA+ICS) for inhalation once daily using the Breezhaler® inhaler.
Fixed combinations of Enerzair® and Atecura® may improve asthma treatment
The newly approved fixed triple combination Enerzair® and the fixed dual combination Atectura® have…
Real Impact of Lockdown on Asthma Treatment – EAACI Survey Results
Restrictions associated with the COVID-19 pandemic have had a significant impact on the treatment…
Articles on this topic
Asthma and Prognosis of Patients with COVID-19
The impact of asthma, its severity, and treatment on the prognosis of patients infected with…
Atectura® and Enerzair® from May 1, 2021 with Health Insurance Coverage
The fixed combination of indacaterol acetate (LABA) and mometasone furoate (ICS) Atectura® and…
Asthma is not a risk factor for a severe course of COVID-19
According to the statement of the Czech Initiative for Asthma from April 2020, the disease…
Omalizumab and Treatment of Severe Refractory Asthma in Pregnant Women
Omalizumab is commonly recommended for the treatment of severe refractory asthma. A special…
Domestic application of biological asthma treatment improves quality of life and reduces doctor visits
The benefits of the possibility of home application of omalizumab, a monoclonal antibody…
Forgotten Pulmonologists: COVID-19 Detection in Patients with Lung Disease
The Czech Pneumological and Phthisiological Society of ČLS JEP (ČPFS) submitted a request to…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- Asthma is not a risk factor for a severe course of COVID-19
- Asthma and nutrition: diet for the primary prevention and treatment of asthma
- Asthma and Prognosis of Patients with COVID-19
- Atectura® and Enerzair®: new fixed dual and triple combination in the treatment of bronchial asthma
- Fixed combinations of Enerzair® and Atecura® may improve asthma treatment
- Forgotten Pulmonologists: COVID-19 Detection in Patients with Lung Disease
Journal on this topic
Related topic